文献速递免疫规划卫生政策与健康促进

用于监测COVID-19疫苗安全性的选定特别关注不良事件(AESI)的背景发病率

Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines.
PubMed 文献 · Vaccine · 2023-04-18

该研究利用澳大利亚新南威尔士州2017–2018年急诊、住院和死亡链接数据,开展回顾性人群队列研究,计算选定的神经系统、血栓栓塞、血小板减少、心肌炎/心包炎、过敏反应和全身性惊厥等AESI的背景发病率(每10万人年),并按年龄和性别分层,估算全国1周和6周预期病例数。结果显示全身性惊厥背景负担较高,吉兰-巴雷综合征(窄定义)率为3.9/10万人年,高于国际报道,血栓栓塞事件率随年龄增加,心肌炎在男性尤其是18–24岁男性中最高。

要点

  • 全身性惊厥在无疫苗接种情况下1周内全国估计1,599–1,872例。
  • 吉兰-巴雷综合征(窄定义)背景率为3.9/10万人年,高于国际报道。
  • 心肌炎在男性中更常见,18–24岁男性最高,1周内全国估计1–4例。

核心结论

  • 利用常规收集的链接医疗数据可提供本地化AESI背景发病率估计,有助于快速评估COVID-19疫苗接种后报告事件的观察值与预期值之比。
  • 该澳大利亚特异性分析提供的AESI背景率可与其他国家比较,以增进对无疫苗接种情况下特定AESI频率地理变异的理解,并可用于项目实施期间的安全性信号检测。

研究设计与样本

  • 回顾性人群队列研究,使用澳大利亚新南威尔士州2017年和2018年急诊、住院和死亡链接数据。
  • 通过国际公认的ICD-10诊断代码识别选定的神经系统疾病、动脉或静脉血栓栓塞性疾病、继发性血小板减少、心肌炎/心包炎以及过敏反应和全身性惊厥的独特事件。
  • 计算每10万人年的州特异性发病率,并在临床相关时按年龄组和性别进一步分层,同时估算全国1周和6周内的预期病例数。

主要发现

  • 除全身性惊厥外,选定的神经系统疾病背景率较低;在无疫苗接种情况下,1周内全国估计全身性惊厥病例为1,599–1,872例。
  • 采用窄病例定义,吉兰-巴雷综合征发病率为3.9/10万人年,高于其他地方报告的国际发病率。
  • 血栓栓塞和脑静脉窦血栓事件发生率随年龄增加。
  • 心肌炎在男性中更常见,且在18–24岁男性中最高,1周内全国估计预期病例为1–4例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Determining background rates of medical conditions identified as adverse events of special interest (AESI) that may occur following COVID-19 vaccination is important for contextualising and investigating potential vaccine safety signals. METHODS: We conducted a retrospective population-based cohort study using linked emergency department, hospitalisation and death data for 2017 and 2018 from Australia's most populous state, New South Wales. Incident cases of select neurological conditions, arterial or venous thromboembolic conditions, secondary thrombocytopenia, myocarditis/pericarditis, and unique events of anaphylaxis and generalised convulsions were identified using internationally agreed upon diagnostic (ICD-10) codes. State-specific rates per 100,000 person-years were calculated, with further stratification by age group and sex where clinically relevant to the condition, and the number of expected cases nationally in one and 6 weeks was estimated. RESULTS: Background rates of selected neurological conditions were low with the exception of generalised convulsions for which 1,599-1,872 cases were estimated nationally in a 1-week period in the absence of vaccination. Using a narrow case definition, rates of Guillain-Barré Syndrome (3.9 per 100,000 person-years) were higher than international rates reported elsewhere. Thromboembolic and cerebral venous sinus thrombosis event rates increased with age. Myocarditis occurred more commonly in males, and was highest in males aged 18-24 years, with an estimated 1-4 cases expected nationally in a 1-week period. CONCLUSIONS: Using routinely collected linked healthcare data provides localised estimates of background rates of new onset or periodic AESI which enables rapid estimation of observed-versus-expected rates of events reported following COVID-19 vaccination. This Australian-specific analysis contributes AESI background rates which can be compared with those from other countries to enhance understanding of geographic variability in the frequency of specific AESI in the absence of vaccination, and can be utilised for signal detection during program implementation.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Pillsbury A, Phillips A, Deng L, et al. Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines. Vaccine. 2023. PMID: 37088604. doi:10.1016/j.vaccine.2023.04.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。